Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4+ T cell subset
- 1 January 1993
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 23 (1) , 299-302
- https://doi.org/10.1002/eji.1830230149
Abstract
Pretreatment of prospective donors of hemopoietic cells with a single recipient-specific blood transfusion can significantly decrease the morbidity and mortality of potentially lethal graft-vs.-host disease (GVHD) in lethally irradiated, allogeneically reconstituted mice. In a previous report we described the requirements for induction of this blood transfusion effect. In the present study we addressed in particular the mechanism underlying this effect. The beneficial effect of blood transfusion appeared to be due to the white blood cell population in the transfused blood. X-irradiation (20 Gy) of the blood prior to transfusion did not abrogate the effect, which makes a veto cell mechanism unlikely. The blood transfusion effect in this model appeared to be mediated by the CD4+ T cell subset, since purified CD4+ spleen cells from transfused donors caused considerably less morbidity and mortality than naive CD4+ spleen cells. Apparently CD8+ cells were not involved, because their absence did not affect the beneficial effect. This observation was further confirmed by the finding that treatment of recipient mice that were reconstituted with spleen cells from transfused donors with anti-CD8 monoclonal antibody (mAb) did not abrogate the blood transfusion effect. Interestingly, the blood transfusion effect was enhanced by administration of anti-CD4 mAb to the recipients. The anti-CD4 mAb might impair the interaction between T cells and antigen-presenting cells, resulting in functional inactivation.Keywords
This publication has 13 references indexed in Scilit:
- Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. I. Requirements for induction and specificity of the effectEuropean Journal of Immunology, 1992
- SUPPRESSION OF GRAFT-VERSUS-HOST REACTIVITY BY A SINGLE HOST-SPECIFIC BLOOD TRANSFUSION TO PROSPECTIVE DONORS OF HEMOPOIETIC CELLSTransplantation, 1991
- Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway.The Journal of Experimental Medicine, 1991
- Prevention of lethal graft‐vs.‐host disease by a single low dose injection of anti‐T cell monoclonal antibody to the allograft recipientsEuropean Journal of Immunology, 1991
- BLOOD TRANSFUSION-INDUCED SUPPRESSION OF DELAYED-TYPE HYPERSENSITIVITY TO ALLOGENEIC HISTOCOMPATIBILITY ANTIGENSTransplantation, 1989
- Immunological unresponsiveness induced by recipient cells transfected with donor MHC genesNature, 1988
- Abrogation of the lethal graft‐vs. ‐host reaction developed to non‐H‐2 antigens: involvement of T suppressor cells distinct from veto cellsEuropean Journal of Immunology, 1987
- ABROGATION OF LETHAL GRAFT‐VERSUS‐HOST REACTION DIRECTED AGAINST NON‐H‐2 ANTIGENS: ROLE OF Mlsa AND K/I REGION ANTIGENS IN THE INDUCTION OF UNRESPONSIVENESS BY ALLOIMMUNIZATIONInternational Journal of Immunogenetics, 1986
- Antigen specific suppression of T-cell responses — the veto conceptImmunology Today, 1985
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivoNature, 1984